[ad_1]
Berlin, July 7, 2022 PRNewswire – Sergei Sagodira, a private biotech company that specializes in radio pharmaceutical products, has announced the appointment of Sergei Sagodira, Chief Business Officer, for the development of radiation and systematic targeting of certain cancers. Appointed from July 1, 2022Serge has overseen all aspects of the company’s business development, using his vast expertise in licensing and marketing for 20 years in business development in the life sciences sector. He works closely with the Ariesim leadership team to establish long-term strategic and value-based partnerships with industry leaders and well-known academic groups in the field of radio pharmaceuticals.
Manfred Rudiger, CEO of Aceum Therapeutics, says PhD.“We are delighted to be able to attract such a highly qualified individual for this important role. Sergei has direct experience in licensing radio pharmaceutical therapies and is well connected in our industry and will bring a global approach to the growth of our business. We look forward to. To work together as we continue to build our lines.
Sergei Sagodira, General Manager of Asium Therapeutics: “I am excited to play this new role in partnership with an experienced team of industry professionals who believe they have the potential to transform the most challenging cancer treatment and ultimately significantly improve patient outcomes. I have been following the progress. I have the privilege of being given the opportunity.
Sergei Aresium has joined Swiss pharmaceutical company Dibiofarm International SA, where he has worked for 10 years in various licensing and marketing roles as director, licensor transactions. Under Serge’s leadership, Debbie, who specializes in oncology and antimicrobial resistance, has also signed licensing agreements with Merk KGaA and Takeda. Sergei has completed a number of licensing transactions on pre-programmed programs. In addition, Serge has spent two years as Director of Business Development at DND, a non-profit R&D organization dedicated to the management of complex collaborative projects. Serge holds a doctorate in life sciences from the University of Tourism. France.
About Asium Therapeutics
Ariesium Therapeutics is a private, clinical-grade radio pharmaceutical company that specializes in diagnosing and treating certain neurodegenerative and other aggressive, difficult-to-treat cancers. The name Ariesium is an example of ‘Marie Curry’, a major contributor to the discovery of radiation and polonium in the treatment of cancer. Systemic Pharmaceutical Product Targeted by Ariesium Leader 177Lu-satoreotide tetraxetan (“satoreotide”) is an antagonist of somatostatin type 2 receptor (SST).2) Excessive stress on neuroendocrine glands (NETs), some severe cancers such as small cell lung cancer (SCLC) and childhood cancer, neuroblastoma, all have few treatment options and poor prognosis. Satoreotide is being developed as a teranolytic pair for radioactive treatment for integrated diagnosis and for these tumors.
Starting in 2021, Ariesium Therapeutics received all rights from Ipsen. Ariesum is headquartered. BerlinWith operations in Germany And now throughout the activities Europe, North America And Australia.
Ariesium is run by a highly experienced management team and is supported by specialized investors EQT Life Sciences (formerly LSP), Health Cap and Pureus Bioventors.
For more information, please visit www.ariceum-therapeutics.com
Source: Asium Therapeutics
[ad_2]
Source link
